Biocon stock price has broken out from the upper band of a Symmetrical Triangle formation, indicating a positive movement.

Biocon shares rose 9% to ₹389, driven by positive developments including Japanese approval for its biosimilar Ustekinumab.

Biocon Ltd has broken out of the Symmetrical Triangle formation on daily charts, suggesting a potential rise in stock price.

Hold Biocon 320-put option as stock may drop to ₹350, with potential for premium increase. Contact [email protected] ...

The rise in Biocon stock was also fuelled after Jefferies upgraded the stock to 'Buy', and raised the target to Rs 400 ...

Biocon Biologics had entered into a settlement and licensing agreement with Janssen Biotech Inc. and Janssen Sciences Ireland ...

Biocon’s subsidiary, Biocon Biologics Limited (BBL), has announced the completion of its first year as a fully integrated ...

Optimism for Biocon is fuelled by the green light for its Bengaluru biologics unit, paired with the USFDA approval for the launch of its Stelara biosimilar for autoimmune disorders, ...

"This is to inform you that Biocon Pharma Limited, a wholly owned subsidiary of the company, has received approval for ...

Biocon's biosimilar Ustekinumab receives regulatory approval in Japan, with Yoshindo Inc. handling commercialization and ...

Biocon Biologics is committed to implementing business expansion in Malaysia. Biocon Biologics is a global company with ...

Biocon Biologics completes one-year as an integrated global biosimilars enterprise: Our Bureau, Bengaluru Wednesday, January 8, 2025, 11:30 Hrs [IST] Biocon Biologics in its first ...